Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.
Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Ninomiya K, et al. Among authors: imamura ck. JTO Clin Res Rep. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107. eCollection 2021 Jan. JTO Clin Res Rep. 2020. PMID: 34589972 Free PMC article. Review.
Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.
Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K. Matsuoka H, et al. Among authors: imamura ck. Oncol Rep. 2012 May;27(5):1393-9. doi: 10.3892/or.2012.1660. Epub 2012 Jan 26. Oncol Rep. 2012. PMID: 22293824
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: imamura ck. Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26. Cancer Sci. 2017. PMID: 28667792 Free PMC article. Clinical Trial.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. Akamatsu H, et al. Among authors: imamura ck. Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2. Int J Clin Oncol. 2019. PMID: 31049758 Free PMC article.
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. Tamura K, et al. Among authors: imamura ck. J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821071 Free PMC article. Clinical Trial.
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
Kawamura T, Imamura CK, Kenmotsu H, Taira T, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Mushiroda T, Takahashi T, Tanigawara Y. Kawamura T, et al. Among authors: imamura ck. Cancer Chemother Pharmacol. 2020 Mar;85(3):605-614. doi: 10.1007/s00280-020-04034-y. Epub 2020 Feb 10. Cancer Chemother Pharmacol. 2020. PMID: 32040702
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
Kenmotsu H, Imamura CK, Kawamura T, Oyakawa T, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Yamamoto N, Takahashi T, Tanigawara Y. Kenmotsu H, et al. Among authors: imamura ck. Cancer Chemother Pharmacol. 2022 Aug;90(2):115-123. doi: 10.1007/s00280-022-04452-0. Epub 2022 Jul 12. Cancer Chemother Pharmacol. 2022. PMID: 35821437
Significance of the comprehensive geriatric assessment in the administration of chemotherapy to older adults with cancer: Recommendations by the Japanese Geriatric Oncology Guideline Committee.
Ninomiya K, Inoue D, Sugimoto K, Tanaka C, Murofushi K, Okuyama T, Watanuki S, Imamura CK, Sakai D, Sakurai N, Watanabe K, Tamura K, Saeki T, Ishiguro H. Ninomiya K, et al. Among authors: imamura ck. J Geriatr Oncol. 2023 Jun;14(5):101485. doi: 10.1016/j.jgo.2023.101485. Epub 2023 Apr 14. J Geriatr Oncol. 2023. PMID: 37062639 Free article. Review.
44 results